June 5, 2008
MethylGene Reports Clinical Data From Phase II Study Evaluating MGCD0103 In Relapsed Or Refractory Non-Hodgkin Lymphomas (PharmaceuticalOnline)
MethylGene Inc. recently announced preliminary data from a Phase II clinical study evaluating MGCD0103, a novel, isoform-selective histone deacetylase (HDAC) inhibitor, in relapsed or refractory non-Hodgkin lymphomas (Trial 008). More…
Filed by Body Scans at 1:00 am under Scan Articles